ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017
Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review.Molecular oncology · 2024Pooled it
- Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer.Scientific reports · 2018Trial
- Diagnostic value of combined serum CEA and CA19-9 in colorectal cancer A meta-analysis.iScience · 2026Article
- Review
- Review
- Fundamentals and research progression on electrochemical sensing of colorectal cancer.Mikrochimica acta · 2025Review
- Design and Fabrication of a 3D-Printed Microfluidic Immunoarray for Ultrasensitive Multiplexed Protein Detection.Micromachines · 2023Article
- Application of Polypyrrole-Based Electrochemical Biosensor for the Early Diagnosis of Colorectal Cancer.Nanomaterials (Basel, Switzerland) · 2023Review
- CYR61 promotes colorectal carcinoma progression via activating epithelial-mesenchymal transition.American journal of cancer research · 2023Article
- Analysis of blood markers for early colorectal cancer diagnosis.Journal of gastrointestinal oncology · 2022Article
- Review
- Cyr61 from adipose-derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin αMolecular oncology · 2021Article
- Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.Bioscience reports · 2021Article
- Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review.Cancers · 2021Review
- Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression.Journal of Cancer · 2021Article
- Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?World journal of gastrointestinal oncology · 2020Review
- Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer.Frontiers in oncology · 2020Article
- Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.Frontiers in pharmacology · 2020Review
- Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer.Translational oncology · 2019Article
- The Diagnostic Value of Serum IGFBP7 in Patients with Esophageal Squamous Cell Carcinoma.Journal of Cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the sensitivity and specificity of serum Cyr61 as a potential biomarker for the diagnosis of colorectal cancer (CRC) and to assess the association between serum Cyr61 level and CRC clinicopathological status.
methodsWe used an enzyme-linked immunosorbent assay to measure serum Cyr61 in patients with CRC, patients with colorectal adenomas, and healthy controls. We also analyzed the relationship between serum Cyr61 and clinicopathological features of CRC patients. The levels of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were quantified using the Roche Cobas 6000 Analyzer. The sensitivity and specificity of Cyr61, CEA, CA19-9 and CEA + CA19-9 were evaluated by receiver operating characteristic (ROC) analysis.
resultsThe serum level of Cyr61 was significantly increased in CRC patients compared with colorectal adenoma patients and healthy controls (p < 0.001). Furthermore, the area under the ROC curve for Cyr61 was 0.935 (95 % confidence interval 0.902-0.968), higher than that for CEA + CA19-9 (0.827, 95 % confidence interval: 0.783-0.871). Use of a Cyr61 cutoff value of 92.0 pg/mL allowed distinguishing CRC patients and healthy controls with a sensitivity of 83 % and a specificity of 97 %. Among CRC patients, an elevated level of serum Cyr61 was significantly associated with more advanced TNM stage (p < 0.0042), lymph node metastasis (p < 0.0088), and vascular invasion (p = 0.0027).
conclusionCyr61 has potential as a serum biomarker for the diagnosis of CRC and for assessment of the clinicopathological status of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.